Blood
Articles in this Issue
First report of AI derived metrics from whole-body MRI in patients with multiple myeloma reveals unique insights into body composition and changes on therapy
Abstract Background: Data on sensitivity and cost effectiveness has shaped national and International Myeloma Working Group guidelines to inc...
Understanding access and treatment challenges in multiple myeloma care
Abstract Background: Multiple myeloma patients face complex barriers to diagnosis, care access, support, and navigation....
RPT1G, a novel hyperbolic NAMPT inhibitor, is highly effective against B-cell non-Hodgkin's lymphoma with germinal center origin
Abstract Background: Germinal center B-cell like (GCB) diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma (NHL), arises f...
First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.
Abstract Introduction Teclistamab was the first approved BCMAxCD3 bispecific antibody for the treatment of patients with relapsed refractory...
Nodal progression in CLL: Real-world predictors of richter transformation and identification of a distinct high-risk NP-CLL subgroup
Abstract Background Aggressive behavior of chronic lymphocytic leukemia (CLL) is relatively uncommon, but in clinical practice, concern for...
Impact of HLA alloimmunization on availability of HLA well matched and mismatched unrelated allogeneic hematopoietic cell donors for transplantation
Abstract Introduction: HLA alloimmunization occurs through exposure to non-self HLA antigens from allogeneic blood products or pregnancy. Th...
Interim analysis of PRO-MIND: Consistent quality of life in elderly patients with R/R DLBCL receiving tafasitamab and lenalidomide
Abstract Background: While there is increasing real-world (RW) evidence on the tafasitamab-lenalidomide (TL) combination in patients (pts) w...
Impact of 1q gain/amplification in multiple myeloma patients treated with daratumumab-based regimens: A retrospective single-center study
Abstract INTRODUCTION Gain/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities...
Propensity score matching analysis comparing the efficacy and long-term outcomes of belumosudil to the best available treatment as a historical control, used as second-line therapy or beyond for chronic GVHD after steroid failure.
Abstract Introduction ROCKstar study demonstrated that Belumosudil (BEL), a selective Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor,...
First-line selinexor plus R-CHOP for high-risk GCB-subtype diffuse large B-cell lymphoma: A multi-center, single-arm, Phase II trial
Abstract Background: The germinal center B-cell-like (GCB) subtype represents the most prevalent molecular classification of diffuse large B...
Comparative suicide risk in hematologic versus solid organ malignancies: A SEER-based competing-risks and cause-specific analysis of 7.4 million reports
Abstract Background: Suicide remains a devastating and under-recognized outcome among cancer patients. While elevated su...
Lupus-like manifestations in MDS/CMML: Evidence for clonal origin and therapeutic implications
Abstract Background Myelodysplastic neoplasms (MDS) and Chronic myelomonocytic leukemia (CMML) can be associated with immune-mediated inflam...
Rapid diagnosis of acute leukemia with integrated epigenetic and genetic profiling
Abstract Introduction Acute leukemia (AL) diagnosis is a complex process that integrates multiple modalities, including histology, flow cyto...
Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy
Abstract Background: Invasive fungal disease (IFD) is a complication of intensive induction chemotherapy (IC) in patients with acute myeloid...
TP53-mutated AML and treatment outcomes in the era of hypomethylating agent/venetoclax therapy
Abstract Background TP53 mutations, present in 5–15% of acute myeloid leukemia (AML) cases, confer poor prognosis and may involve 17p deleti...
Real world outcomes of FLT3 inhibitors and hypomethylating agents as post transplant prophylaxis in Acute Myeloid Leukemia patients transplanted in first complete remission: From the EBMT acute leukemia working party
Abstract Introduction: Allogeneic hematopoietic stem cell transplantation (HSCT) remains a mainstay in the treatment of acute myeloid leukem...
Bispecific antibody vs non-bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T-cell (CART) failure in large B-cell lymphoma
Abstract Background For patients with large B-cell lymphoma (LBCL) who relapse after CART, optimal next line therapy is unknown. Bispecific...
Patients with AML with an IDH2 R172K mutation have improved overall survival with venetoclax + azacitidine as compared to those with IDH2 R140Q mutations
Abstract Introduction: Mutations in the Kreb's cycle enzyme isocitrate dehydrogenase 2 (IDH2) and its homolog, isocitrate dehydrogenase 1 (I...
Upfront vs posttherapy allogeneic stem cell transplantation for high-risk myelodysplastic syndrome – a real-world analysis in the era of molecular risk stratification
Abstract Background: For patients with high-risk myelodysplastic syndromes (MDS) or borderline acute myeloid leukemia (AML), the timing of a...
Single center retrospective evaluation of CHOP-based regimens in older patients with treatment naive blastic plasmacytoid dendritic cell neoplasm
Abstract BACKGROUND: Blastic plasmacytoid dendritic cell neoplasm (BPCDN) is an extremely rare and aggressive hematologic malignancy. Severa...
Impact of recipient sociodemographic factors on allogeneic transplant conditioning intensity and survival outcomes in myeloid malignancies: A secondary analysis of CIBMTR data
Abstract Introduction: Sociodemographic factors influence all aspects of the allogeneic hematopoietic cell transplantation (HCT) process. Th...
Point-of-care musculoskeletal ultrasound in hemophilic arthropathy: Evidence synthesis, clinical impact, and recommendations for multidisciplinary implementation
Abstract Objective: To synthesize and critically evaluate the existing body of evidence on the diagnostic performance, clinical integration,...
HOXA9/METTL3/BMI1 axis is required for promoting anthracycline resistance in acute myeloid leukemia cells by modulating BMI1 expression through mRNA m6A modification
Abstract Background Acute myeloid leukemia (AML) is the most common adult acute leukemia. The traditional “3+7” induction regimen with anthr...
Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database
Abstract Introduction TP53MT are associated with poor outcomes in MDS, especially in the context of biallelic MT. We have previously reported...
Assessing the utility of the charlson comorbidity index in predicting outcomes of CAR-T therapy in patients with diffuse large B-cell lymphoma
Abstract Background: The Charlson Comorbidity Index (CCI) is a widely used tool for assessing comorbidity burden and predicting clinical outc...